According to a press release from GE Healthcare, Arven Pharmaceuticals, a Turkish pharmaceutical company, has selected GE Healthcare’s FlexFactory platform to increase its manufacturing capacity. GE describes FlexFactory as a centrally automated, flexible biomanufacturing platform that is primarily comprised of single-use technologies, associated process hardware, and integrated control components for start-to-finish manufacturing of biopharmaceuticals. FlexFactory is described as cell-line agnostic, meaning that it has the potential to be scaled to manufacture any biopharmaceutical product given the right approach during process development.
According to one report, Arven Pharmaceuticals intends to use FlexFactory to support its biosimilars pipeline, which is said to include biosimilars for various oncology and autoimmune indications.
Stay tuned to Big Molecule Watch for more updates.